Clinical Trials
35 trialsBASECAMP-1
A2 Biotherapeutics Inc.
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
ABILITY-1
Medicenna Therapeutics, Inc.
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
MESODEC
University Hospital, Antwerp
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Dendritic Cell Vaccination for Patients with Solid Tumors
University Hospital, Antwerp
Immuno-MESODEC
University Hospital, Antwerp
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
CAMP1
Mabpro, a.s.
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
REGOMUNE
Institut Bergonié
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Augusta University
Clinical and Histopathologic Characteristics of BAP1 Mutations
Memorial Sloan Kettering Cancer Center
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
Fox Chase Cancer Center
E-MOSAIC Electronic Tool to Monitor Symptoms
Swiss Cancer Institute
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
Kantonsspital Winterthur KSW
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
National Institutes of Health Clinical Center (CC)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)